Abcellera Biologics Inc (ABCL)

$3.56 -0.06 (-1.66%)
Market Cap 1.08B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 4,914,457
Avg Vol 4,084,268
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 2%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
tradersunion353
tradersunion353 Feb. 2 at 7:16 PM
$ABCL Sad to see this dropping and day like this when market is sharply up
1 · Reply
nUme22
nUme22 Feb. 2 at 6:24 PM
$ABCL under 3 again
0 · Reply
Samb2344
Samb2344 Feb. 2 at 5:50 PM
$ABCL I bought the dip so yall would stop complaining 🫡🤣
0 · Reply
GuslovesBio
GuslovesBio Feb. 2 at 5:35 PM
$ABCL Kyowa Kirin just disclosed Kaposi Sarcoma in a “high risk” patient treated with their OX40 antibody. The technicals won’t save you long term in a biotech stock. Their lead asset has issues and there is no other news right now so we sink until an asset or partnership creates value. (or not).
1 · Reply
Ckkung71
Ckkung71 Feb. 2 at 4:36 PM
$ABCL Seventh day in a row, here we go..
0 · Reply
Chebsmcgee
Chebsmcgee Feb. 2 at 3:13 PM
$ABCL sold this two weeks ago to go all in on tungsten plays. Port up 34%, profits will gradually cycle back While this continues its monthly trend of hitting 3.2, bouncing to mid 4’s and getting stronger, I’ll build in slowly
1 · Reply
tradersunion353
tradersunion353 Feb. 2 at 2:58 PM
$ABCL For the love of the longs bleefing needs to stop and we want to see reversal
1 · Reply
DeMampCamp
DeMampCamp Feb. 2 at 2:47 PM
$ABCL 300,000 shares on the ask at $3.61? Shorts using this time to cover?
1 · Reply
DeMampCamp
DeMampCamp Feb. 2 at 2:46 PM
$ABCL I fully expect to be seeing insider transactions, they should be buying up every single share down here in the mid $3S
0 · Reply
Targhee
Targhee Feb. 2 at 2:28 PM
$ABCL must be getting close to some kinda news ….cause I’ve just about had it…🤞🤣🤣
0 · Reply
Latest News on ABCL
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 10 days ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 9:16 PM EST - 18 days ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 21 days ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 6 weeks ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 7 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 8, 2025, 1:37 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 3 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 3 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 4 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 5 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 5 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 6 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 9 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 9 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 9 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 9 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

tradersunion353
tradersunion353 Feb. 2 at 7:16 PM
$ABCL Sad to see this dropping and day like this when market is sharply up
1 · Reply
nUme22
nUme22 Feb. 2 at 6:24 PM
$ABCL under 3 again
0 · Reply
Samb2344
Samb2344 Feb. 2 at 5:50 PM
$ABCL I bought the dip so yall would stop complaining 🫡🤣
0 · Reply
GuslovesBio
GuslovesBio Feb. 2 at 5:35 PM
$ABCL Kyowa Kirin just disclosed Kaposi Sarcoma in a “high risk” patient treated with their OX40 antibody. The technicals won’t save you long term in a biotech stock. Their lead asset has issues and there is no other news right now so we sink until an asset or partnership creates value. (or not).
1 · Reply
Ckkung71
Ckkung71 Feb. 2 at 4:36 PM
$ABCL Seventh day in a row, here we go..
0 · Reply
Chebsmcgee
Chebsmcgee Feb. 2 at 3:13 PM
$ABCL sold this two weeks ago to go all in on tungsten plays. Port up 34%, profits will gradually cycle back While this continues its monthly trend of hitting 3.2, bouncing to mid 4’s and getting stronger, I’ll build in slowly
1 · Reply
tradersunion353
tradersunion353 Feb. 2 at 2:58 PM
$ABCL For the love of the longs bleefing needs to stop and we want to see reversal
1 · Reply
DeMampCamp
DeMampCamp Feb. 2 at 2:47 PM
$ABCL 300,000 shares on the ask at $3.61? Shorts using this time to cover?
1 · Reply
DeMampCamp
DeMampCamp Feb. 2 at 2:46 PM
$ABCL I fully expect to be seeing insider transactions, they should be buying up every single share down here in the mid $3S
0 · Reply
Targhee
Targhee Feb. 2 at 2:28 PM
$ABCL must be getting close to some kinda news ….cause I’ve just about had it…🤞🤣🤣
0 · Reply
JennyRowes
JennyRowes Feb. 1 at 3:05 PM
$ABCL where can find insider sales information going back at least 2 years?
1 · Reply
Kaykay610
Kaykay610 Jan. 31 at 1:34 PM
$ABCL not worried one bit!!! Everything will play out this year, even the doggy/kitty clincal field studies are set to finish this year. We bout to have solutions for mature aged lonely single women and they can bring all 19 cats we have something for everyone. Dmd treatment moved from active to complete so bring the step kids to
1 · Reply
Ed_Ng
Ed_Ng Jan. 30 at 9:26 PM
$ABCL I told them to take profit but they laughed at me. Now they cry 😿
0 · Reply
Ed_Ng
Ed_Ng Jan. 30 at 9:25 PM
$ABCL bear market or sideway, stock going down is acceptable. But during the last 3 years where there has been massive bull market but this stock is still lagging and trending down = no hope business
0 · Reply
Ckkung71
Ckkung71 Jan. 30 at 9:24 PM
$ABCL Strange weak. 1/4 of the company. No bad news. Mostly good last month. Have the shorters so much power to make the moves like that?
1 · Reply
EdwardJL
EdwardJL Jan. 30 at 9:13 PM
$ABCL Buy for the potential, stay for the drama. I remain
0 · Reply
DeMampCamp
DeMampCamp Jan. 30 at 9:11 PM
$ABCL Well, that was a nasty close! Thankfully it’s the weekend! Cheers, everyone!
0 · Reply
Plutten1973
Plutten1973 Jan. 30 at 8:00 PM
$ABCL If u have patience u will be rewarded, only been here for about 5 years ,have patience for many years more!
0 · Reply
WenMoon9
WenMoon9 Jan. 30 at 7:37 PM
$ABCL i really hope y'all sold at 4.50
3 · Reply
Odoji
Odoji Jan. 30 at 7:05 PM
$ABCL we hanging strong considering they trying to liquidate the entire world 🤣
1 · Reply
tradersunion353
tradersunion353 Jan. 30 at 5:17 PM
$ABCL The stock has been in a steady downtrend since the conference. Really hoping we see this sell-off end at some point.
1 · Reply
AGC_Trader
AGC_Trader Jan. 30 at 3:56 PM
$ABCL A clear "bearish double top" formed on the daily chart. Let's see if it finds support here or at the bottom of the accumulation range (lower $3.30 s)
2 · Reply